Safety and Immunogenicity of inactivated COVID-19 vaccine in Thai adults

ational Reseach Council, Thailand0 个研究点目标入组 182 人开始时间: 2021年3月8日最近更新: 2024年8月19日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 182

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The seroconversion rate of total antibodies against RBD after the first CoronaVac dose was 67% with a Geometric mean concentration (GMC) of 1.98 U/ml. Following CoronaVac dose 2, the seroconversion rate increased to 100% with a GMC of 92.9 U/ml. The seroconversion rates of IgG against N protein were 1% after dose 1 and 62.8% after dose 2.

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 Years 至 60 Years（—）
性别: All

入选标准

•1. Healthy Thai adults aged between 18-60 years
•2. Willing to be immunized with COVID-19 vaccine
•3. Intend to be available for follow-up visits and phone call through 12 months postvaccination

排除标准

•1. Subjects with history of COVID-19, asymptomatic SARS-CoV-2 infection or pre-existing antibodies to SARS-CoV-2
•2.Previous severe reaction or allergy to any components in the COVID-19 vaccine
•3.History of hospitalization within the past one month before injection.
•4.Serious underlying medical condition (e.g., immunosuppressive disease or receiving immunosuppressive therapy, human immunodeficiency virus (HIV) infection)
•5.Pregnant women, lactating women or women who are planning to become pregnant

研究者

发起方

ational Reseach Council, Thailand

相似试验

已完成

不适用

Safety and immunogenicity of inactivated COVID-19 vaccine and virus vector vaccine in Thai adults with previous infection: Clinical trialHealthy but had been previously infected with COVID-19safety, immunogenicity, inactivated, virus vector COVID-19, vaccine

TCTR20210520004The National Research Council of Thailand120

Unknown

不适用

Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical WorkersSARS-CoV-2 InfectionCovid19

NCT04795414Ruijin Hospital1,370

Unknown

4 期

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis PopulationHemolysisCOVID-19

NCT05480436China National Biotec Group Company Limited1,200

Unknown

4 期

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies VaccineCOVID-19Rabies

NCT05453487China National Biotec Group Company Limited360

已完成

4 期

Immunogenicity of an Inactivated COVID-19 VaccineCOVID-19

NCT05198336Sinovac Research and Development Co., Ltd.395